Implantable artificial kidney project making progress
Editor’s note: The implantable artificial kidney is being developed jointly by the University of California San Francisco and Vanderbilt University Medical Center. Nephrology News & Issues is not involved in the development of the device and cannot help anyone become a participant in a clinical trial.
Vanderbilt University Medical Center nephrologist and associate professor of medicine William H. Fissell IV, MD, is making major progress on an implantable artificial kidney. The device uses microchip filters and living kidney cells that will be powered by a patient’s own heart.
Fissell has been working on the implantable artificial kidney for more than a decade with University of California San Francisco bioengineer Shuvo Roy, PhD. In November 2015, the National Institutes of Health awarded a four-year, $6 million grant to the investigators to develop the implantable artificial kidney. In 2003, the project attracted its first NIH funding, and in 2012 the Food and Drug Administration selected the project for a fast-track approval program.
“We are creating a bio-hybrid device that can mimic a kidney to remove enough waste products, salt and water to keep a patient off dialysis,” said Fissell. Fissell says the goal is to make it small enough, roughly the size of a soda can, to be implanted inside a patient’s body.
The key to the implantable artificial kidney is a microchip, Fissell said.“It’s called silicon nanotechnology. It uses the same processes that were developed by the microelectronics industry for computers,” said Fissell.
The chips are affordable, precise and make ideal filters. Fissell and his team are designing each pore in the filter one by one based on what they want that pore to do. Each device will hold roughly fifteen microchips layered on top of each other.
The logical progression of dialysis treatment improvements would be portable (think a smaller, lighter version of the NxStage System One), wearable, and implantable. And through the Kidney Research Institute and the University of Washington, Jonathan Himmelfarb, MD, is working on the wearable. Read more
The microchips are also the scaffold in which living kidney cells will rest, said Fissell. His team is using live kidney cells that will grow on and around the microchip filters. The goal is for these cells to mimic the natural actions of the kidney.
“We can leverage Mother Nature’s 60 million years of research and development and use kidney cells that fortunately for us grow well in the lab dish, and grow them into a bioreactor of living cells that will be the only “Santa Claus” membrane in the world: the only membrane that will know which chemicals have been naughty and which have been nice. Then they can reabsorb the nutrients your body needs and discard the wastes your body desperately wants to get rid of,” said Fissell.
Because this bio-hybrid device sits out of reach from the body’s immune response, it is protected from rejection.
“The issue is not one of immune compliance, of matching, like it is with an organ transplant,” said Fissell.
How the implantable artificial kidney works
The device would operate naturally with a patient’s blood flow.
“Our challenge is to take blood in a blood vessel and push it through the device. We must transform that unsteady pulsating blood flow in the arteries and move it through an artificial device without clotting or damage,” Fissell said.
Vanderbilt biomedical engineer Amanda Buck is using fluid dynamics to see if there are certain regions in the device that might cause clotting. She uses computer models to refine the shape of the channels for the smoothest blood flow. Then they rapidly prototype the new design using 3-D printing and test it to make the blood flow as smoothly as possible.
Fissell says he has a long list of dialysis patients eager to join a future human trial. Pilot studies of the silicon filters could start in patients by the end of 2017.
“My patients are absolutely my heroes,” said Fissell. “They come back again and again and they accept a crushing burden of illness because they want to live. And they’re willing to put all of that at risk for the sake of another patient.”
For more information on the project, visit kidney.ucsf.edu